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Endogenous Retroviruses (ERVs) are “fossilized” retroviruses of a once 
exogenous retrovirus located in the genome of extant vertebrates. Retroviral 
infection results in a provirus integration into the host genome. An infection of a 
germline cell could lead to the provirus potentially being inherited by the offspring 
of the infected individual. Once in the genome, the provirus becomes subject to 
evolutionary processes and can become either lost or fixed in a population, 
remaining as “fossils” long after the exogenous retrovirus has gone extinct23. 
 
Notably, 8% of the human genome consists of ERVs30. Human Endogenous 
Retrovirus Type K (HERV-K)(HML-2) family is of particular interest. HERV-K 
integrations are as old as 30-35 million years, endogenizing before the separation 
of humans and Old World Monkeys. However, there are human specific insertions, 
some as young as 150,000 – 250,000 years, making them the youngest insertion 
in the human genome. There are over 90 insertions in the human genome; the 
bulk is shared by all humans44,47. Transcripts of HERV-K genes are upregulated in 
multiple cancer and tumor cell lines 14,39,46, as well as in HIV-1 infected patients 
7,11,29.  
 
Just as there are human specific insertions of ERV-K, there are also Old World 
Monkey specific insertions44. I have identified an intact endogenous retroviral 
envelope open reading frame on chromosome 12 of the rhesus macaque genome. 
This viral envelope-encoding sequence, which I refer to as rhERV-K env, retains 
all the canonical features of a retroviral Env protein. An alignment between rhERV-
K env and a consensus sequence of HERV-K, HERV-Kcon env, shows a 70% 
amino acid sequence identity.  
 
For experimental purposes, reconstructed HERV-K envelopes have been 
incorporated into virions of Human Immunodeficiency virus (HIV-1)19,26,49, Murine 
Leukemia Virus (MLV)12, and Vesicular stomatitis Virus (VSV)26,41,49. While these 
approaches have illuminated some aspects of HERV-K Env-mediated entry, to 
date a cell-surface receptor has not been identified for any ERV-K Env. This could 
be due to its low infectivity levels12,26,49, its seemingly broad cell tropism limiting 
identification of null cell lines26,49, or possibly the HERV-K consensus 
reconstructions are not an accurate representation of the progenitor HERV-K virus.  
 
I am interested in understanding how the ERV-K retrovirus accessed the human 
germline (some 150,000 – 250,000 years ago). To do this, I focused specifically 
on the envelope proteins of HERV-K and rhERV-K, with the goal of analyzing the 
ERV-K entry process. The identification and inclusion of rhERV-K Env in this study 
is meant to circumvent the possibility that the previously described consensus 
reconstructions of human HERV-K Env are not representative, and may also 
provide a means to compare the endogenization process in the human/ape and 
old-world monkey lineages. I focused on developing two systems for single-cycle 
infection, one based on Mason-Pfizer Monkey Virus (MPMV) (which has not been 
done before), and a second based on MLV, which has previously been reported 
on. MPMV, like HERV-K, is a betaretrovirus, and I reasoned that possibly using a 
betaretrovirus would overcome some of the low-infectivity issues associated with 
prior attempts using HIV and MLV.  
 
To develop a system for examining function of the ERV-K Env proteins, I 
addressed 3 issues: 
1. Are the HERV-K Env and rhERV-K Env proteins expressed and properly 
processed? 
2. Can they be incorporated into virions of a heterologous virus? 
3. Are ERV-K pseudotyped virions infectious? 
I have answered these questions in the following thesis. 
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CHAPTER 1: INTRODUCTION 
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1.1 Retroviruses 
Retroviruses are enveloped single-stranded positive sense RNA viruses which 
replicate via a double-stranded DNA intermediate that integrates into the host 
genome becoming simply a new set of cellular genes. The virus can then be 
transmitted indefinitely by the cell during DNA replication and cell division50. 
Retroviruses have been isolated from numerous animal species, including fish, 
mice, chicken, cats, cattle, horses, monkeys, and humans24. Most notorious of the 
retrovirus family are the Lentiviridae, such as the Human Immunodeficiency Virus 
(HIV), a sexually transmitted virus discovered in the mid-1980s50. This particular 
retrovirus caused a worldwide epidemic of acquired immune deficiency syndrome 
(AIDS) which has claimed the lives of millions of people and still remains rampant 
in many parts of the world.  
 
Retrovirus virions are spherical enveloped particles about 100 nm in diameter and 
are characterized by the presence of reverse transcriptase (Figure 1)9,50. The virion 
contains two copies of the viral positive-stranded RNA genome, complexed with 
the nucleocapsid protein (NC). The genome is capped at the 5’ end and 
polyadenylated at the 3’ end. After infection and reverse-transcription, the DNA 
provirus is flanked by 5’ and 3’ Long Terminal Repeats (LTRs), which contain a 
150- to 200-nt repeated sequence (R) with unique regions adjacent at either end 
designated U5 and U3. Downstream of the U5 is the primer binding sequence 
(PBS) in which a specific cellular transfer RNA (tRNA) binds, serving as the primer 
for the initiation of synthesis of DNA complementary to the genome RNA.  
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The retroviral genome consists of three major genes, each translated as a 
polyprotein: gag, pol and env. The gag gene encodes the nucleocapsid protein 
(NC), the capsid protein (CA), which forms an icosahedral or conical core, and the 
matrix protein (MA), which coats the inner surface of the membrane. The pol gene 
encodes the viral enzymes that are associated with the viral core: a protease (PR), 
an integrase (IN), and a reverse transcriptase (RT). The env gene encodes the 
envelope protein (Env) containing an external surface protein (SU), bound by 
noncovalent interactions to the transmembrane protein (TM). All these viral 
proteins are synthesized as polyproteins, which are cleaved by viral and cellular 
proteases into the individual viral proteins that then assemble to form an infectious 
virion 9,50. 
 
 
Figure 1. Retrovirus. A typical retrovirus structure. 
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The retrovirus is defined by its unique replication cycle which is based on reverse 
transcription and integration of its genome (Figure 2)9,50. A retrovirus recognizes 
and binds to a receptor on the host cell, which then mediates fusion and entry into 
the cell. The capsid is released into the cell cytoplasm and the RNA genome is 
reverse transcribed into double-stranded DNA (dsDNA). The dsDNA is imported 
into the nucleus, where it is integrated into the host cell genome and is now termed 
the provirus. The proviral genes become transcribed and translated. Env proteins 
are translated at the endoplasmic reticulum (ER) and transported through the Golgi 
apparatus and the endosomal compartment before arriving at the plasma 
membrane. In contrast, Gag and Gag-Pol proteins are translated in the cytosol and 
interact with each other to initiate assembly of the viral core. The viral proteins then 
assemble at the cellular membrane where the virion buds from the host cell; this 
activates the viral protease, which cleaves Gag and Pol into their individual 
structural and enzymatic proteins rearranging into a mature virion. At this stage the 
virion is infectious and can begin its replication cycle anew 9. 
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Figure 2. Retroviral Life Cycle. 1. A retrovirus recognizes and binds to the receptor on 
the host cell mediating fusion and entry into the cell. 2. The CA is released into the 
cytoplasm. 3. The RNA is reverse transcribed into dsDNA. 4. The dsDNA integrates into 
the host genome, and is now termed the provirus. 5. The proviral genes are transcribed 
and translated. 6. The Env proteins are transported through the Golgi apparatus arriving 
at the plasma membrane. The Gag and Pol proteins are translated in the cytosol 
assembling the viral core. 7. The viral proteins assemble at the cell membrane. 8. The 
virion buds and matures. 
 
1.2 Endogenous Retroviruses  
Endogenous Retroviruses (ERVs) are remnants of a once exogenous retrovirus 
located in the genome of extant vertebrates 24. Retroviral infection results in a 
provirus integration into the host genome (Figure 3). If present in the germ line 
cells, the provirus could potentially be inherited and can persist by vertical 
transmission. Once in the genome, the provirus becomes subject to evolutionary 
processes and can become either lost or fixed in a population, remaining as 
“fossils” long after the exogenous retrovirus has gone extinct. The majority of these 
“fossilized” retroviruses, however, are unable to produce infectious virions 
because of mutations that disrupt reading frames or gene expression.  
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Figure 3. Process of Endogenization. A retroviral infection of a germline cell results in 
a provirus integration into the host genome. Once in the host genome, it becomes subject 
to evolutionary processes and can become lost or fixed in a population remaining as 
“fossils” long after the exogenous retrovirus has gone extinct.  
 
ERVs have been found in many vertebrate genomes, including fish 20, mice 2,33, 
lemurs 17, rabbits 25, colugos 18, koalas 45, armadillos 35, cats16,22, dogs16,36, sheep5, 
pandas37, multiple simian species6,43,48, humans12,47,49, and many more. 
Sequencing information has revealed a significant portion of vertebrate genomes 
consisting of ERVs, with about 8% in the human genome30, for example. 
Interestingly, some ERV genes have been adapted by the host organism for new 
and specialized functions. A well-known example is the env gene of human 
endogenous retrovirus W, syncytin-115,31. Syncytin-1 is a cell-cell fusion protein 
expressing during fetal development which acts in the formation of the fused 
trophoblast layer of the cells surrounding the fetus. ERVs have also been coopted 
7 
for viral resistance. For example, Refrex-1 is a truncated Env encoded by ERV-
DC7 and ERV-DC16 that acts as an antiretroviral factor in domestic cats inhibiting 
infection by feline leukemia virus subgroup D22,34. Friend virus susceptibility protein 
4 in mice, derived from an endogenous ecotropic Murine Leukemia Virus (MLV), 
protects from exogenous MLV infection33,34. Expression of endogenous Jaagsiekte 
sheep retrovirus (enJSRV) Env in sheep restricts exogenous JSRV infection3,4. 
These data suggests that these remnants of a once exogenous retrovirus not only 
serve as “fossils” within the genome but have contributed to genomic evolution in 
multiple species. 
 
1.3 Human Endogenous Retrovirus Type-K Family 
Human Endogenous Retrovirus Type-K (HERV-K)(HML-2) family includes the 
most recently formed proviral integrations44,47 in humans found to date. While the 
presence of HERV-K(HML-2) sequences in humans and Old World Monkeys 
indicates that the group is 30 – 35 million years old, there are human-only 
insertions thought to have integrated as recent as 150,000 – 250,000 years 
ago44,47. Thus, the human genome has proviruses that contain nearly intact 
reading frames, with few or no mutations and proteins that remain functional in 
vitro. However, there are no replication-competent HERV-K viruses found 
exogenously. There are over 90 proviral insertions and over 1,000 solo long 
terminal repeats (LTRs) present in the human genome, the bulk of which is shared 
by all humans44,47. Transcripts of HERV-K genes are upregulated in multiple 
8 
cancer and tumor cell lines10,14,39,40, as well as in HIV-1 infected patients7,11,29, 
indicating its potential for contributing to human genomic evolution.  
 
Previous work has been conducted with reconstructed ancestral HERV-K 
consensus sequences, HERV-Kcon and Phoenix12,19,49. While there is no 
replication-competent HERV-K virus, expression of the HERV-Kcon and Phoenix 
proviruses produces virus-like particles that weakly infect human and nonhuman 
cell lines12,49. Prior studies on individual HERV-K proteins showed Gag was 
functionally expressed and processed into MA, NC, and CA10,13,27. Gag and Pro 
proteins mediated efficient assembly and processing of virus-like particles. 
Furthermore, Env was functionally expressed and processed into its two 
subunits12,49. HERV-K Env from both HERV-Kcon and Phoenix reconstructions 
displayed a broad cell tropism, infecting a range of human and nonhuman cell 
lines13,26,42,49. Env was also shown to inhibit tetherin32, a restriction factor blocking 
the release of viral particles from the host cell by keeping them tethered to the cell 
surface. HERV-Kcon was also shown to resist inhibition from the human restriction 
factor apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 
(APOBEC) 3G, but it is inhibited by APOBEC 3F32. These data elucidate possible 
characteristics for the now-extinct HERV-K virus. Because of the very recent 
integration of HERV-K, researchers have a rare opportunity to understand the 
process of endogenization as it is occurring within the human genome through 
extensive characterization and functional studies of the proviral sequences. 
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1.4 Retrovirus Envelope  
The process of endogenization is still relatively poorly understood. Endogenization 
begins upon retroviral entry into the host cell, mediated by Env proteins. Studying 
Env of the most recently endogenized retrovirus family, HERV-K, can elucidate the 
early stages of endogenization through functional characterization. The HERV-K 
family resembles retroviruses in the Betaretrovirus subfamily44,47. Viruses that 
belong to this group include JSRV, mouse mammary tumor virus (MMTV), enzootic 
nasal tumor virus (ENTV), and Mason-Pfizer monkey virus (MPMV). The Envs of 
viruses within this subfamily strongly dictate viral tropism through receptor 
recognition.  
 
Envelope mediates retroviral fusion and entry into a host cell9,21. Unprocessed 
envelope contains a signal peptide domain (SP), a surface subunit (SU), and a 
transmembrane subunit (TM) (Figure 4). The SP initiates transmembrane 
synthesis in the ER and ultimately is cleaved off by a host signal peptidase. During 
Env processing, the Env becomes N-glycosylated in the endoplasmic reticulum 
and the Golgi apparatus9. The host-protease furin then cleaves the SU-TM 
precursor at the furin cleavage site, generating the two subunits, which are 
noncovalently associated as hetero-trimers on the cell surface. The SU subunit is 
responsible for receptor recognition, while the TM subunit mediates fusion and cell 
entry. Only fully processed envelope can mediate retroviral fusion and entry in the 
cell. Through functional characterization of HERV-K Env, we can understand how 
the retrovirus first accessed the human germline 150,000 – 250,000 years ago.  
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Figure 4. Envelope processing. Full-length envelope contains a signal peptide (SP) 
domain which initiates transmembrane synthesis and is cleaved by a host peptidase. The 
Env becomes N-glycosylated and is cleaved at the furin cleavage site (FC) by endogenous 
proteases. The SU and TM subunits are noncovalently associated as trimers on the cell 
surface. SU - surface subunit. TM - transmembrane domain. Y – glycosylation sites.  
 
Just as there are human-specific insertions of ERV-K, there are also Old World 
Monkey specific insertions. Focusing on the rhesus macaque genome, I identified 
an intact endogenous retroviral envelope open reading frame on chromosome 12. 
Soon thereafter, a group published the same findings of ERV-K proviral insertions 
on chromosome 12, while also finding two other insertion sites on chromosomes 
5 and 1148. This viral envelope-encoding sequence, referred to as rhERV-K Env, 
retains all the canonical features of a retroviral Env protein, and spliced mRNA 
product encoding rhERV-K Env was isolated from macaque cells19. An alignment 
between rhERV-K env and HERV-K env shows an 82% amino acid sequence 
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identity (APPENDIX B). These data suggest that rhERV-K env potentially retains its 
original function.  
 
1.5 Open Questions 
To date, there are no exogenous replication competent HERV-K viruses. In order 
to functionally characterize HERV-K Env, an infectious system using Env must be 
made. The unique retroviral lifecycle can be exploited in a process called 
pseudotyping (Figure 5). Env and Gag-Pol proteins are translated in different parts 
of the cell and united at the cell surface to form a virion. We can exploit this by 
expressing ERV-K Env in trans with Gag-Pol from a heterologous retrovirus to 
create a pseudotyped virions, with which functional studies of ERV-K Env can be 
conducted.  
 
Figure 5. Process of pseudotyping virions. To make functional ERV-K virions, ERV-K 
Env are expressed in trans with Gag-Pol of a heterologous retrovirus. The proteins 
assemble at the cell surface forming an ERV-K pseudotyped virion. 
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Infectious systems using HERV-K Env have been established. For experimental 
purposes, Gag-Pol cores of Human Immunodeficiency Virus (HIV-1)19,26,49, Murine 
Leukemia Virus (MLV)12, and Vesicular stomatitis Virus (VSV)26,42,49 were 
pseudotyped with reconstructed HERV-K envelopes. While these approaches 
have illuminated some aspects of HERV-K Env-mediated entry, to date a cell-
surface receptor has not been identified for any ERV-K Env. This could be due to 
its low infectivity levels12,26,49, its seemingly broad tropism, limited identification of 
ERV-K null cell lines13,26,49, or possibly the HERV-K consensus reconstructions are 
not an accurate representation of the progenitor HERV-K virus.  
 
To understand how the ERV-K retrovirus accessed the germline, I focused 
specifically on the envelope proteins of HERV-K and rhERV-K, with the goal of 
analyzing the ERV-K entry process. The identification and inclusion of rhERV-K 
Env in this study is meant to circumvent the possibility that previously described 
consensus reconstructions of human HERV-K Env are not representative, and it 
may also provide a means to compare the endogenization process in the 
human/ape and Old-World monkey lineages. I focused on developing a system 
based on MPMV, which has not been attempted before, and MLV, which has been 
previously done. MPMV, like HERV-K, is a betaretrovirus, and I reasoned that 
using a betaretrovirus core could overcome some of the low-infectivity issues 
associated with prior attempts using HIV and MLV cores. 
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To develop a system for examining function of the ERV-K Env proteins, I had to 
address three issues: 
1. Are the HERV-K Env and rhERV-K Env proteins expressed and properly 
processed? 
2. Can they be incorporated into virions of a heterologous virus? 
3. Are ERV-K pseudotyped virions infectious? 
Here, I describe the development of a single-cycle ERV-K infectious system based 
on MPMV. 
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CHAPTER 2: MATERIALS AND METHODS 
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2.1 ERV-K sequences 
The env gene of the HERV-Kcon reconstructed ancestral HERV-K(HML-2) was 
previously described49. To find the rhERV-K env, HERV-Kcon Env was used as a 
probe in a tblastn search in the genome of Macaca mulatta. A fully intact rhERV-K 
env was found in the Macaca mulatta BAC clone CH250-211O116 from 
chromosome 12 (AC200900.3). The rhERV-K env sequence is described in 
APPENDIX A. 
2.2 Cell lines 
Human embryonic kidney 293T cells (HEK293T) (ATCC CRL-11268; American 
Type Culture Collection, Manassas, VA), human lung carcinoma A549 cells (ATCC 
CCL-185), and feline kidney CRFK cells (ATCC CCL-94) were maintained at 37̊C 
and 5% CO2 in Dulbecco’s modified Eagle medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 25mM HEPES. 
2.3 Plasmids 
The env gene of the HERV-Kcon reconstructed ancestral HERV-K(HML-2) and a 
codon-optimized version of the env gene of rhERV-K with an N-terminal AviTag 
were ordered from GeneArt (ThermoFisher Scientific). Both HERV-Kcon env and 
rhERV-K env were cloned into pcDNA3.1(+) and pCRV1 expression vectors (gift 
of Paul Bieniasz, Rockefeller University) using EcoRV and NotI sites, producing 
the plasmids pcDNA3.1-HERV-Kcon env, pcDNA3.1-rhERV-K env, pCRV1-
HERV-Kcon env, and pCRV1-rhERV-K env. Envelope constructs were cloned 
without the AviTag, pCRV1-HERV-Kcon env ΔAviTag and pCRV1-rhERV-K env 
ΔAviTag. pVSV-G (ClonTech) was used as a positive envelope control for 
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pseudotyping virions. Production of pseudotyped Mason Pfizer Monkey Virus 
(MPMV) virions was carried out using pSARM-EGFP (produced by WE Diehl). 
Production of pseudotyped Murine Leukemia Virus (MLV) virions was carried out 
using pCIGB and pLXIN-EGFP. 
2.4 Viruses 
To make ERV-K pseudotyped virions, pCRV1 envelope constructs without the 
AviTag were used. Pseudotyped virions were produced by cotransfection of 
HEK293T/17 cells with appropriate plasmids using GenJet Transfection Reagent 
(SignaGen Laboratories, Ijamsville, MD). Briefly, 600,000 – 750,000 HEK293T/17 
cells were seeded per well in a 6-well plate the day before transfection. For 
transfection in a T75 flask, 7.5 x 106 cells were seeded. At 48 hours after 
transfection, supernatant was collected and centrifuged at 1,500 rpm for 5 min. 
The resulting supernatant was used for infection. Pseudotyped MPMV virions were 
produced by cotransfection of a 1:1 ratio of envelope (pCRV1-HERV-Kcon env 
ΔAviTag, pCRV1-rhERV-K env ΔAviTag, or pVSV-G) and pSARM4-EGFP. 
Pseudotyped MLV virions were produced by cotransfection of envelope, pLXIN-
EGFP, and pCIGB.  
2.5 Transfection  
600,000 HEK293T/17 cells were seeded in 6-well plates the day before 
transfection. For protein expression, 1 ug of DNA was transfected using 6 uL 
GenJet reagent. At 48 hours after transfection, cells were lysed with 200 ul of cold 
IP Lysis Buffer for 5 – 10 min on ice and added in a 1:1 ratio of 2X Laemmli buffer. 
To harvest viral supernatant for western blot, the supernatant was centrifuged at 
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3,000 rpm for 5 min. The supernatant was then added to 6.5 ml of D10 and filtered 
through a 0.45 μm membrane. The cleared supernatant was layered on 3 ml of 
20% sucrose and centrifuged at 35,000 rpm for 1.5 hours at 4̊C (Rotor SW41TI). 
The media was aspirated and the virion pellet was resuspended in 100 ul of 2X 
Laemmli buffer. The samples were then heated at 99̊C for 10 min and used for 
western blot. 
2.6 Western Blot 
Samples were run on a 10% polyacrylamide gel: 4.1 ml of H2O, 3.3 ml of 30% 
Acrylamide, 2.5 ml of 1.5 M Tris-HCl pH 8.8, 100 ul of 10% SDS, 100 ul of 10% 
Ammonium persulfate (APS), 5 ul of TEMED. The proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane in a wet transfer apparatus at 100V / 
gel overnight at 4̊C. Membranes were then blocked with 5% milk in PBST (0.05% 
Tween-20 in PBS) for at least 1 hour and primary antibody was added overnight 
at 4̊C. The membranes were washed with PBST in 10 minute intervals for 50 
minutes and secondary antibody was added for one hour. The membranes were 
washed as previously described and exposed. The following primary antibodies 
were used: 1:1000 Mouse Anti-HERV-K Env (AUSTRAL Biologicals HERM-1811-
5), 1:500 Rabbit Anti-MPMV CA. The secondary antibodies were at a dilution of 
1:5000.  
2.7 Infectivity Assay 
600 ul of the virion supernatant was added to 50,000 cells per well in a 12-well 
plate seeded the day before infection. At 4 - 5 hours after infection, 500 ul of warm 
D10 was added to each well. At 48 hours after infection, cells were imaged for 
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GFP+ cells. For FACS analysis, cells were washed with 150 ul of warm trypsin. 150 
ul of warm trypsin was added to the cells until no longer adherent. 1 ml of D10 was 
added to the wells. The cells were centrifuged at 1,500 rpm for 5 minutes and 
resuspended in 150 ul of 2% paraformaldehyde in PBS. 
2.8 Concentrating Virions  
7.5 x 106 HEK293T/17 cells were seeded in a T75 flask a day before transfection. 
8 µg of DNA was transfected in the cells using the GenJet Transfection Reagant. 
At 48 hours after transfection, the supernatant was removed and centrifuged at 
1,500 rpm for 5 minutes. The resulting supernatant was then added to YM-50 
Centriprep Centrifugal Filter Unit with Ultracel-50 membrane columns (Millipore 
Sigma 4311). The supernatant was centrifuged twice, once at 1,500 g for 10 
minutes, and a second time at 1,500 g for 5 minutes. The concentrated virions 
were added to cells as previously described.  
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CHAPTER 3: RESULTS 
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3.1 rhERV-K env 
To find the rhERV-K env, HERV-Kcon Env was used as a probe in a tblastn search 
in the genome of Macaca mulatta. A fully intact rhERV-K env was found in the 
Macaca mulatta BAC clone CH250-211O116 from chromosome 12 (AC200900.3). 
The codon optimized rhERV-K env was created via GeneArt’s algorithm and the 
gene was ordered via GeneArt (APPENDIX A). 
 
3.2 Expession of ERV-K Envs 
To test expression of rhERV-K Env and confirm expression of HERV-Kcon Env, 
expression plasmids were transfected in triplicate into HEK293T cells and the cell 
lysates were harvested 48 hours after transfection. Expression was not detectable 
by western blot using the pcDNA3.1(+) vector. However, when envs were cloned 
into the pCRV1 vector, expression was detected via western blot. A western blot 
using anti-HERV-K Env antibody showed expression and processing of full-length 
HERV-Kcon and rhERV-K Envs, with protein products showing up around 103 kDa 
and 38 kDa, for full-length and processed Env respectively (Figure 6). Notably, the 
antibody against HERV-K Env cross-reacts and can detect rhERV-K Env. 
Furthermore, the western blots demonstrate that processing of the Envs is 
incomplete since there were high levels of full-length envelope expression.  
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Figure 6. Expression of ERV-K Envelopes. 1 µg pCRV1 HERV-Kcon env and pCRV1 
rhERV-K env were transfected into HEK293T cells and cell lysates were harvested. A 
western blot against the transmembrane domain (TM) of HERV-Kcon Env revealed full-
length (FL) unprocessed and TM subunits; the presence of both a FL and TM band 
indicates partial processing of the Env polyproteins. 
 
Expression of the envelopes occurred using the pCRV1 vector, but did not occur 
in the pCDNA3.1(+) vector because transcripts were unable to export out of the 
nucleus. pCRV1 encodes HIV-1 Rev and has a Rev Response Element (RRE). 
RNA transcripts are spliced to produce Rev, which is imported into the nucleus 
after translation. Rev binds the RRE of the transcribed RNAs before splicing and 
exports the unspliced and partially spliced transcripts into the cytoplasm38. 
Translation can then occur. The envelopes in the pCDNA3.1(+) vector were 
transcribing mRNA (RT-PCR data not shown), but translation was not occurring, 
indicating that mRNA was getting stuck in the nucleus. This problem was 
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overcome by cloning the envelopes in the pCRV1 backbone, which contained rev 
and an RRE. 
 
3.3 Pseudotyping MPMV particles 
 
Figure 7. Pseudotying MPMV with ERV-K Envs. ERV-K envs were cotransfected with 
MPMV gag-pol. The producers cell lysates were harvested to check for protein expression 
via western blot. The supernatants were harvested to check for virion release via western 
blot. 
 
ERV-K envelope constructs, as well as a VSV-G-encoding construct as a positive 
control, were cotransfected with MPMV gag-pol Δenv plasmids. The producer cell 
lysates were harvested and visualized by a western blot to look for ERV-K Env and 
MPMV CA expression (Figure 7). A western blot of the producer cell lysates stained 
for HERV-K Env showed expression and processing of full-length HERV-Kcon and 
rhERV-K Envs (Figure 8). A western blot against MPMV CA showed CA expression 
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in the producer cells. This data illustrates proper expression of viral proteins in the 
producer cells.  
 
Figure 8. Western blot of Producer Cell Lysates. Producer cells were cotransfected 
with 0.5, 1, 1.5, and 2 µg of ERV-K envelope constructs and 1 µg of pSARM4-EGFP. The 
producer cell lysates were harvested 48 hours after transfection and checked for Env and 
MPMV Capsid (CA) expression. There is Env expression and processing of both HERV-
Kcon Env and rhERV-K Env. There is also MPMV CA expression in the producer cell 
lysates indicating that the producer cells were making all proteins required for the 
production of ERV-K pseudotyped virions. 
 
If the Envs were incorporated into virion particles, then Env-pseudotyped virions 
would be released from the cell into the supernatant. To test for incorporation, the 
virions in the supernatant were pelleted and analyzed by western blot to check for 
ERV-K Env and MPMV CA protein release (Figure 1Figure 9). An Env-only control 
was used to determine the amount of background release of Env into the 
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supernatant without an MPMV core. A western blot probed for expression of 
HERV-K Env showed full-length and processed HERV-Kcon and rhERV-K Envs in 
the supernatant indicating Env release. A western blot probed for MPMV CA 
revealed CA release into the supernatant, indicating that both ERV-K Envs were 
incorporated into MPMV virions that were released into the supernatant.  
 
It’s important to note high levels of full-length Env in the supernatant, which 
indicates full-length Env incorporation into MPMV virions. It is possible 
incorporation of full-length uncleaved Env into virions may interfere with infectivity 
(Figure 9). Furthermore, a 1:1 ratio of env to MPMV gag-pol is optimal for 
incorporation to occur, as evidenced by the highest levels of both Env and MPMV 
CA in the viral supernatant (lane indicated by the [*] asterisk). 
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Figure 9. Western blot of Virions in the Supernatant. Producer cells were cotransfected 
with 0.5, 1, 1.5, and 2 µg of ERV-K envelope constructs and 1 µg of pSARM4-EGFP. The 
supernatant was harvested and checked for Env and MPMV Capsid (CA) release. There 
is full-length and processed Env release for both HERV-Kcon Env and rhERV-k Env, as 
well as CA release in the supernatant indicating ERV-K Envs were incorporated into 
MPMV and were released from the cell. The Env only control serves as the background 
for Env release without MPMV CA.  
 
3.4 Infectivity of ERV-K Pseudotyped Virions 
2 mls of the supernatants from the producer cells containing the pseudotyped 
virions were added to HEK293T/17, A549, and CRFK cells (Figure 10). At 48 hours 
after infection, the cells were harvested for FACS analysis.  
* * 
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Figure 10. Infectivity Experimental Design. ERV-K env plasmids were co-transfected 
with MPMV gag-pol at 1:1 ratio (1µg each). The supernatant was harvested 48 hours after 
transfection and added to two human cell lines, HEK293T and A549, and one feline cell 
line, CRFK. At 5 hrs after infection, 500 ul of warm D10 was added. At 48 hrs after 
infection, the cells were harvested for FACS analysis. 
 
ERV-K pseudotyped virions were able to mediate entry into CRFK cells, but not 
HEK293T/17 cells and A549 cells (Figure 11). The positive control VSVG-MPMV 
mediated entry into 80% of CRFK cells. FACS analysis revealed that the highest 
levels of infectivity occurred with the 1:1 ratio of transfected env to MPMV gag-pol. 
At this optimum ratio, HERV-Kcon MPMV infected 0.22% of CRFK cells, whilst 
rhERV-K Env MPMV infected 0.032% of CRFK cells. However, rhERV-K MPMV 
infectivity, while suggesting fusion and entry into the cell, is inconclusive. There 
was no entry of the ERV-K pseudotyped virions in the human cell lines, 
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HEK293T/17 and A549. The VSVG positive control infected HEK293T/17 and 
A549 cells at a low rate of 0.42% and 33.6%, respectively. Therefore, no 
conclusions can be drawn from those cell types.  
 
 
Figure 11. FACS Analysis of ERV-K Pseudotyped MPMV Virions on different cell 
types. Both HERV-Kcon and rhERV-K Env pseudotyped MPMV virions were able to infect 
CRFK cells, but were unable to infect A549 and HEK293T cells. The positive control was 
VSVG pseudotyped MPMV, which was able to infect CRFK cells at a high level, A549 at 
a mediocre level, and unable to infect HEK293T indicating a technical issue. hu – human 
cell line.  
3.5 Increasing Infectivity of ERV-K Pseudotyped MPMV virions 
In order to develop an infectious system, I sought to increase infectivity in CRFK 
cells. First, the optimum time to harvest virions after transfection of the plasmids 
was determined. 2 ml of supernatants were harvested 24, 36, and 48 hours after 
transfection and added to CRFK cells. At 48 hours after infection, the cells were 
harvested for FACS analysis. The data revealed that harvesting supernatant at 
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later time points increased ERV-K pseudotyped MPMV virion infectivity in CRFK 
cells (Figure 12). Harvesting virions at 48 hours after transfection was optimal and 
it increased the infectivity two-fold from previous experiments. HERV-Kcon MPMV 
infected up to 0.47% of CRFK cells, while rhERV-K MPMV infected up to 0.13% of 
CRFK cells.  
 
 
Figure 12. FACS Analysis of Infectivity of ERV-K Pseudotyped MPMV virions 
harvested at 24, 36, and 48 hrs after transfection. Pseudotyped virions harvested 48 
hours after transfection were able to infect CRFK cells at the highest level. No Env was 
used as the Gag-Pol-only negative control. The Envs only were also used as a background 
control.  
 
To further increase infectivity of pseudotyped virions, concentrating columns were 
used to concentrate virions. 7.5 x 106 HEK293T/17 cells were seeded and 
transfected with the plasmids. 14 ml of virion supernatant were collected and 
concentrated to 4 ml of virion supernatant using YM-50 concentrating columns. 
Both unconcentrated and concentrated virions were used to infect CRFK cells and 
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48 hours after infection, the cells were harvested for FACS analysis (Figure 13). 
Since VSVG-MPMV virions previously demonstrated a 94% infectivity level, 
VSVG-MPMV virions were diluted 15-fold and then concentrated. Unconcentrated 
VSVG-MPMV virions infected 13.3% of CRFK cells, while concentrated VSVG-
MPMV virions infected 27.3% of CRFK cells. Concentrating ERV-K pseudotyped 
MPMV virions slightly increased infectivity. Unconcentrated HERV-Kcon MPMV 
infected 2.8% of CRFK cells, while concentrated virions infected 3.8% of CRFK 
cells. Unconcentrated rhERV-K MPMV infected 1.4% of CRFK cells, while 
concentrated virions infected 1.7% of CRFK cells. The data reveals that 
transfecting a higher amount of cells increases infectivity as shown by 
unconcentrated virions, and that concentrating the virions using the concentration 
columns increased infectivity slightly.  
 
Figure 13. Concentrating ERV-K Pseudotyped MPMV Virions slightly increased 
infectivity. No Env was the Gag-Pol-only negative control. VSVG MPMV was used as the 
positive control and was diluted 1:15 before concentrating.  
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3.6 Addition of exogenous furin 
According to Figure 9, there is a significant amount of full-length envelope in 
released virions. Full-length envelope could potentially be incorporated into MPMV 
virions interfering with infectivity. Only processed envelope can mediate fusion and 
entry into the cell. To increase processing of envelope, a furin construct was 
cotransfected with the envelope constructs. At 48 hours after transfection, cells 
were lysed. A western blot against HERV-K Env revealed that addition of 
exogenous furin did not increase processing of full-length envelope (Figure 14). 
Interestingly it did change the banding pattern of full-length envelope revealing 
proteins at the 103 kDa and 79 kDa mark as compared to the 103 kDa protein in 
the full-length envelope ERV-K Env without addition of furin, most likely indicating 
different glycosylation patterns.  
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Figure 14. Addition of Exogenous Furin to the ERV-K Envs. Co-transfection of ERV-
K env plasmids and furin expression plasmids did not yield significantly higher envelope 
processing.  
 
3.7 Pseudotyping MLV Virions  
Previous reports have demonstrated HERV-Kcon Env incorporation with MLV 
cores. I sought to pseudotype MLV virions to develop an ERV-K infectious system 
based on MLV. HEK293T/17 cells were co-transfected with varying amounts of 
envelope constructs ranging from 0.3 µg to 2 µg, varying amounts of MLV gag-pol 
Δenv ranging from 0.3 µg to 2 µg, and varying amounts of packagable GFP 
construct ranging from 0.3 µg to 2 µg. The plasmids were transfected at varying 
ratios of env: gag-pol: gfp. At 48 hours after transfection, 2 mL of virion supernatant 
were harvested and placed onto HEK293T/17 and CRFK cells. At 48 hours after 
infection, cells were imaged for GFP+ cells. While VSVG-MLV virions were able to 
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infect both HEK293T/17 cells and CRFK cells, ERV-K pseudotyped MLV virions 
were unable to infect either cell type.   
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CHAPTER 4: DISCUSSION 
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I have developed a single-cycle ERV-K infectious system based on MPMV. While 
HERV-K-based single-cycle systems based on lentiviruses and 
gammaretroviruses exist, this is the first report of an HERV-K infectious system 
based on MPMV, a betaretrovirus.  I also discovered an ERV-K Env homolog in 
the rhesus macaque genome, referred to as rhERV-K Env. rhERV-K Env was 
expressed, processed and found capable of incorporating into MPMV virions. This 
is the first report of functional characterization of a rhERV-K Env. 
 
In order to create an ERV-K infectious system, ERV-K Envs need to be functional. 
I have demonstrated that both ERV-K Envs are expressed and processed (Figure 
6). This is the first report showing rhERV-K Env expression in vitro.  To detect the 
expression of the envelopes, an antibody against HERV-K Env TM was used. This 
antibody cross reacted with the rhERV-K Env. This is of interest because the 
antibody recognizes and binds to the TM of HERV-K Env and rhERV-K Env. 
However, the primary amino acid sequences of the TM regions of the two Envs 
differ quite a bit (APPENDIX B) so the recognition of the antibody must be at the 
conserved sites of the HERV-Kcon TM and rhERV-K Env TM.  
 
The sizes of the full-length and processed envelopes were as predicted, 103 kDa 
and 38 kDa respectively. The smear of the processed envelope products in the 
western blot in Figure 6 is likely due to post-translational glycosylation altering the 
sizes. Notably, the envelopes were not fully processed as indicated by the 
presence of the full-length envelope in the western blot. Co-transfection of the 
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envelope constructs with exogenous furin constructs did not increase processing 
of full-length envelope, but instead slightly changed the banding pattern of the 
western blot showing a full length protein at size 79 kDa, which is the size of the 
full length protein with no glycosylation. This indicates that co-expression with 
exogenous furin possibly altered the glycosylation patterns of the full-length 
envelope (Figure 14).  
 
Expression of the envelope could only occur from a pCRV1 backbone and did not 
occur from a pcDNA3.1(+) backbone.  pCRV1 encodes for HIV-1 Rev and contains 
a RRE to which Rev can bind, mediating transport of unspliced RNA out of the 
nucleus. RT-PCR performed on RNA extracted from HEK293T cells transfected 
with pcDNA3.1(+) ERV-K showed that ERV-K transcripts were being made (data 
not shown), but the lack of expression detected via western blot indicates that the 
problem was probably a failure of ERV-K ENV mRNA to export out of the nucleus.  
 
Incorporation of ERV-K Env into MPMV virions was successful and pseudotyped 
virions mediated fusion and entry into CRFK cells, indicating that CRFK cells 
express the receptor required for HERV-Kcon and rhERV-K Env recognition 
(Figure 8, Figure 9, Figure 11). This is the first report demonstrating that rhERV-K 
Env is functional, can pseudotype MPMV virions, and can mediate fusion and entry 
into a cell. However, infectivity of the ERV-K pseudotyped MPMV virions in CRFK 
cells is low. This could be due to full-length envelope incorporation into virions. As 
shown in Figure 9, there was a significant amount of full-length envelope being 
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incorporated into MPMV virions. Full-length envelope is unable to mediate fusion 
and entry into the cell. Only processed envelope is able to mediate fusion and entry 
into the cell. Unfortunately, co-transfecting furin expression plasmids with the ERV-
K envs did not increase envelope processing (Figure 14).  
 
In order to increase infectivity of the ERV-K pseudotyped MPMV virions, the virions 
were concentrated using YM-50 concentrating columns. The samples were 
centrifuged in the concentrating columns twice, concentrating the virions from a 14 
ml volume to a 4 ml volume. This yielded slightly higher infectivity, up to ~4% for 
HERV-Kcon pseudotyped MPMV virions, and up to ~2% for rhERV-K pseudotyped 
MPMV virions (Figure 13). It is also notable that scaling up the amount of virus-
producing cells from a 6-well to a T75 flask increased infectivity, as shown in Figure 
13. Scaling up the amount of virus-producing cells increased the amount of virions 
in the supernatant, which in turn would increase infectivity on CRFK cells.  
 
Future experiments should be aimed to further increase the infectivity levels of the 
ERV-K pseudotyped MPMV virions to characterize ERV-K entry and to identify the 
receptor for the ERV-K Envs. One of the simplest approaches would be to increase 
the amount of virions in the supernatant to concentrate. This study transfected 7.5 
x 106 HEK293T/17 cells to make pseudotyped MPMV virions. The virions in the 
supernatant from the transfection were concentrated to a smaller volume. If double 
the amount of HEK293T/17 cells were transfected, more virions would be created. 
By concentrating a larger number of virions into a smaller volume, there would be 
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more virions to recognize the receptor and mediate fusion into the cell, potentially 
increasing infectivity levels.  
 
Another simple method to improve infectivity would be to try infecting other cell 
types and lines. In the interest of time, this study only focused on CRFK cells. 
However, there are various cell lines that could potentially express the receptor on 
the surface of the cell in higher quantities. Because of increased receptor 
expression, the ERV-K pseudotyped virions would be able to recognize the 
receptor and mediate fusion and entry more easily than in a cell line with sparse 
cell receptor expression. CRFK cells are feline cells. While my data indicates that 
CRFK cells express the ERV-K receptor on the cell surface, it is highly likely that 
rhERV-K Env is better adapted to use its orthologous receptor on rhesus macaque 
cells. This study did not use rhesus macaque cell lines for infectivity. It is probable 
that rhesus macaque cell lines express the receptor for rhERV-K Env and it is 
important to test the infectivity of rhERV-K pseudotyped virions on rhesus-origin 
cells. However, it does remain possible that rhERV-K env have been coopted for 
viral resistance. Even though rhesus macaque cells lines express the receptor for 
rhERV-K Env, endogenous rhERV-K env could be downregulating expression of 
the receptor inhibiting exogenous infection. 
 
Unfortunately, pseudotyping MLV with the ERV-K Envs was unsuccessful. In 
parallel to creating an ERV-K based system in betaretroviruses, I sought to create 
an ERV-K based system in gammaretroviruses since it was previously reported. 
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While the control, pseudotyping with VSVg was successful, there was no infectivity 
seen with ERV-K pseudotyped MLV. A possible explanation is that Serinc5, a 
cellular protein with antiviral effects, is reducing the infectivity of the pseudotyped 
MLV virions. A recent paper identified that co-transfection of virus-producing cells 
with a Serinc5 expression plasmid reduced infectivity and entry of MLV and this 
was determined by envelope meaning that different envelopes resulted in 
differential susceptibility to Serinc51. MLV encodes a glycosylated form of gag, 
glycogag, which counteracts the effects of Serinc5. It was demonstrated that a 
small amount of Glycogag was able to counteract endogenous Serinc5 in 
HEK293T cells1. Thus, for this study, Serinc5 in the virus-producing HEK293T cells 
could have potentially been reducing the infectivity of pseudotyped MLV virions. 
This effect was not seen with VSVg pseudotyped MLV virions, which could explain 
why the control worked well, but the ERV-K pseudotyped virions did not. To test if 
this is the case, virus-producing plasmids need to be co-transfected with a MLV 
glycogag expression plasmid. Since it was previously demonstrated that even a 
small amount of Glycogag can counteract endogenous Serinc5 in HEK293T cells, 
it is predicted that this experiment would result in increased infectivity of ERV-K 
pseudotyped MLV virions.  
 
Once the ERV-K infectious system is optimized to high infectivity levels, ideally 
around 80-100% (but lower infectivity levels will work), it can be utilized to find a 
receptor. In order to do that, the cell tropism of both envelopes must be determined. 
It stands to reason that some cell lines will be refractory to infection by ERV-K-
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MPMV, indicating a lack of receptor expression. Once such a null cell line and at 
least one permissive cell line are identified, two main strategies can be pursued to 
find the receptor. The first is through a cDNA library screen, which has been 
previously successfully used to identify receptors for other viral envelopes8,43. 
Once null cell lines and permissive cell lines are established, a packagable cDNA 
library from the permissive cell line will be created. The permissive cell line will 
contain the transcript for the receptor. The permissive cell line cDNA library will be 
transduced into the null cell line and ERV-K pseudotyped GFP-expressing virions 
will be used to infect the transduced null cell line. The cells will be screened for 
permissivity by means of GFP expression. GFP+ cells will be isolated by flow 
cytometry and expanded. Genomic DNA will be extracted from those cells any 
transduced genes will be identified by PCR. Once potential target genes are 
identified, gain-of-function studies and loss-of-function studies will identify the 
receptor of ERV-K. 
 
The second method to identify the cell surface receptor is a proteomics approach 
similar to the one used to find the SARS Coronavirus receptor28. Briefly, soluble 
ERV-K envelope proteins fused to a tag will be incubated with the cell extracts of 
permissive cell lines. The mixture will be put through a column containing beads 
designed to bind to the tag. After multiple washes, elution of the soluble envelope 
and the bound proteins will occur. This eluate will then be run on a SDS-Page gel 
and the bands will be cut out and analyzed via mass spectrometry.  
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This study is the initial step in figuring out how ERV-K retroviruses accessed the 
human germline some 150,000 – 250,000 years ago. Since there is no exogenous 
replication competent HERV-K, an infectious system is required to characterize 
the envelope proteins and identify the receptor. This was the first study 
demonstrating that ERV-K envelope proteins can be incorporated into MPMV 
virions. Furthermore, this is the first study showing that rhERV-K Env is functional 
and can mediate fusion and entry into CRFK cells. This infectious system, once 
optimized, can be used to find a receptor for this once exogenous retrovirus. Using 
this infectious system, we can determine how this virus accessed the germline cell 
in the first place and learn more about the early stages of endogenization.  
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APPENDIX A 
Leader Sequence 
Furin Cleavage Site 
Fusion domain 
Immunosuppressive Domain 
Conserved Cysteine Residues 
Transmembrane Anchor Domain 
 
rhERV-K env sequence (AC200900.3).  
ATG AAC CCA TCG GAG ATG CAA AGA AAA GCG CCT CCA CGG AGA CAG AAA  
   M       N        P        S        E        M       Q        R       K        A        P        P        R        R        Q       K 
CAC CGC AAT CGA GCA CCA TTG ACT CGC ATG ATG AAC CAA GTG ATG ATA  
   H        R        N        R        A        P       L        T        R       M        M       N        Q       V       M        I 
TCA GAA GAA CAG ATG AAG TCA CCA CGC ACC AAG AAG GCG GAG CTG CCG  
   S        E        E        Q       M       K        S        P        R       T        K        K         A        E        L        P 
ACC TGG GCA CAG TTA AAG AAG CTG ACA CCG TTA GCT GGA AAA AGC CTA 
    T       W        A       Q        L       K        K        L        T        P        L       A        G        K        S        L 
GCT AGC ACA AAG GTG ACA CAA ACC CCA GAA AAA ATG CTG CTT ACA GCT  
    A       S        T        K        V        T        Q       T        P        E        K       M        L        L       T        A 
TTA ATG ATT GTA TCA ACG GTG GTA AGT CTC CCC ATG CCT GCA GGA GCA 
    L      M        I        V       S        T         V        V       S        L        P        M        P       A        G        A 
GCT GCA GCT AAT TAT ACC TAC TGG GCC TAT GTG CCT TTC CCG CCC TTA  
   A        A         A      N       Y        T       Y        W        A       Y        V        P       F        P        P        L 
ATT CGG GCA GTT ACA TGG ATG GAT AAT CCT ATT GAA GTA TAT GTT AAT AAT 
    I        R        A        V        T       W       M        D       N       P        I        E        V       Y        V       N       N 
 AGT GTG TGG GTA CCT GGT CCC ACA GAT GAT CGT TGC CCT GCC AAA CCG  
    S        V        W        V       P        G        P        T        D       D        R       C        P        A        K       P 
GAG GAA GAA GGA ATG ATG ATA AAT ATT TCC ATT GGG TAT CGT TAT CCT  
    E        E        E        G       M        M       I        N        I       S         I        G        Y       R       Y        P 
CCT ATT TGC CTA GGG AGA GCA CCA GGA TGT TTA ATG CCT GCT ATT CAA  
   P        I        C        L        G        R        A        P        G       C        L       M        P       A        I        Q 
AAT TGG TTG GTA GAA GTA CCT ACT GTC AGT CCC ACC AGT AGA TTT ACT  
   N       W       L        V        E        V        P       T        V        S        P       T        S        R       F        T 
TAT CAC ATG GTA AGC GGA ATG TCA CTC AAA CCA CAG GTA AAC TAT TTA  
   Y       H        M        V       S        G       M        S        L       K        P       Q        V       N        Y       L 
CAA GAC TTT TCT TAT CAA AGA TCA TTA AAA TTT AGG CCA AAA GGG AAA CCT  
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   Q        D       F       S       Y        Q       R       S        L       K       F       R        P        K        G        K       P 
TGC CCC AAA GAG ATT TCC AGA GAA TCG AAA GAT TTA GTT TGG GAA GAA  
    C        P       K        E        I        S        R        E       S        K        D       L        V       W       E        E 
TGT GTG GCC GAT AGT GCA GTG ATA TTA CAA AAC AAT ACA TTC GGA ACA  
   C        V        A        D        S        A        V        I        L       Q       N        N       T       F        G        T 
 
GTT ATA GAT TGG GCA CCT AGA GGT CAA TTC TAC CAC AAT TGC ACA GGA 
    V       I        D       W        A        P        R       G        Q       F        Y       H        N       C        T       G 
CAA ACT CAA TTC TGT CCC AGT GCA CTA GTG AGT CCA ACT GTT GAC AGT  
   Q        T        Q      F        C        P       S         A        L       V        S        P       T        V        D        S 
GAT TTA ACG GAA AAT TTA GAT AAA CAT AAG CAC AAA AAA TTA CAG TCT TTC  
   D        L       T         E       N       L       D        K       H       K        H       K        K       L       Q       S        F 
TAC CCT TGG ATA TGG GGA GAA AAG GGA ATG TCT ACT CCA AGA CCA AAA  
   Y        P       W        I        W        G        E       K        G        M       S       T        P        R       P        K 
ATG ATA AGT CCT GTT TTT GGT CCT GAA CAT CCA GAA TTA TGG AGA CTT  
   M        I        S        P        V       F       G        P        E       H        P        E       L       W       R        L 
ACT GTG GCT TCA TAC CGC CTT AGA ATT TGG TCT GGA AAT CAA ACT ATA  
   T        V        A       S        Y        R        L       R        I        W       S        G       N        Q       T        I 
GAA ACA AGA GAT TAT AAG CCA TTT TAC TCT ATC AAC CTA AAT TCC AGT CTA  
    E       T        R        D       Y       K        P       F       Y        S        I        N        L       N       S        S        L 
ACA GTT CCT TTA CAA AGT TGT GTA AAG CCC CCT TAT ATG TTA GTC ATA  
   T         V       P       L       Q        S       C        V       K        P        P        Y       M       L       V        I 
GGA AAT ATA GTT ATT AAA CCA GAC TCC CAA ACT ATA ACT TGT GAA AAT TGC  
    G       N        I        V        I        K       P        D        S       Q        T        I        T        C       E        N       C 
AGA TTG TTT ACT TGC ATT GAT TCA ACT TTT GAT TGG CAG CAC CGT ATT CTA  
   R        L        F       T       C        I        D        S       T       F        D       W        Q       H        R        I        L 
CTG GTG AGA GCA AGA GAA GGC GTG TGG ATC CCT GTG TCC ATG GAC CGA  
    L       V         R       A        R        E        G        V        W        I        P        V        S        M       D        R 
CCA TGG GAG GCC TCA CCA TCC ATC CAT ATT TTG ACT GAA GTA TTA AAA  
    P       W        E        A        S        P       S         I        H        I        L       T        E        V       L        K 
GGC GTT TTA AGT AGA TCC AAA AGA TTC ATT TTT ACT TTA ATT GCA GTG ATT  
    G        V       L       S        R        S       K        R       F        I        F       T        L       I         A        V        I 
ATG GGA TTA ATT GCA GTC ACA GCT ACA GCC TCT GTG GCA GGA GTT GCA  
   M       G        L        I        A        V       T         A       T        A        S        V        A        G        V       A 
TTG CAC TCT TCT GTT CAG ACA GTA AGC TTT GTT GAC AAT TGG CAA AAG  
   L        H       S       S        V       Q        T        V        S       F        V       D        N       W       Q        K 
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AAT TCC ACA AGG TTG TGG AAT TCA CAA TCT GGT ATC GAT CAA AAA TTG  
   N       S        T        R        L       W       N        S       Q       S        G        I        D        Q       K        L 
GCA AAT CAA ATT AAT GAT CTT AGA CAA ACC GTC ATT TGG ATG GGA GAT  
    A       N       Q        I        N       D        L       R        Q       T        V        I        W       M        G       D 
AGA CTC ATG AGC TTG GAA CAT CGT TTC CAG TTA CAG TGT GAC TGG AAT  
   R        L        M       S        L        E       H        R        F       Q        L       Q        C       D       W        N 
ACG TCA GAT TTT TGT ATT ACA CCC CAA GTT TAT AAT GAG TCT AAA CAT CAC  
   T        S        D       F       C        I        T        P        Q        V       Y       N       E        S       K        H       H 
TGG GAC ATG GTT AGA CGC CAT CTA CAG GGA AGA GAA GAT AAT CTC ACT  
   W        D       M        V       R        R        H        L       Q        G        R        E        D       N       L        T 
TTA GAC ATT TCT AAA TTA AAA GAA CAA ATT TTT GAA GCC TCT CAA AGC CAC  
   L        D        I       S        K       L       K        E        Q       I        F       E        A       S        Q        S        H 
TTA AAT ATT GTG CCT GGA GCT GAG GCA TTA GAT CAA GTG GCA AAA AAT  
   L       N        I        V        P        G        A        E        A        L       D        Q       V        A        K       N 
CTT TAT GAA TTA AAC CCC ACG ACT TGG ATT AAG TCT ATT GGA AAC TCT ACT  
    L      Y        E       L        N        P        T        T        W       I        K       S        I         G       N        S       T 
GCA ATA AAT TTT GGA ATT ATG TGT CTC TGT TTA ATC AGC TTG TTT TTA GTG  
    A        I        N        F        G        I        M       C        L        C        L        I         S         L       F        L        V 
TGC TGG ACC AGT CGA AGA ATC CTG CGT CAA AAT CGA GAG AAC GAA CAA  
   C        W       T        S        R        R        I         L        R       Q        N       R        E        N        E       Q 
GCC TTC ATC GCC ATG GCA CAT TTA TAT AGA GGA AAA GGG AGG GAG AAC  
    A       F        I         A        M       A        H       L       Y        R       G        K        G        R         E       N 
GTT GCG GGA AGT CAG GGA CCT TGA 
    V       A        G        S        Q        G       P         *         
 
 
 
 
 
 
 
 
 
 
44 
rhERV-K codon-optimized env sequence.  
ATGAATCCCAGCGAAATGCAACGGAAAGCTCCCCCTAGGCGACAGAAGCAC
AGGAACCGCGCCCCTCTGACCAGAATGATGAACCAGGTGATGATCAGCGA
GGAACAGATGAAGTCACCACGCACAAAAAAAGCGGAACTGCCCACATGGG
CCCAGCTGAAGAAGTTGACTCCACTTGCAGGTAAATCCCTGGCATCCACCA
AGGTGACTCAGACTCCCGAAAAGATGCTTCTGACTGCTCTTATGATCGTGTC
CACCGTGGTGTCCCTGCCTATGCCTGCCGGCGCCGCCGCCGCAAACTATA
CCTACTGGGCCTACGTCCCCTTTCCCCCTCTCATCAGGGCAGTGACTTGGA
TGGACAATCCCATCGAGGTGTATGTCAATAATAGCGTGTGGGTACCCGGAC
CTACGGACGACAGGTGTCCAGCAAAGCCTGAGGAGGAAGGCATGATGATT
AATATAAGTATCGGATACCGGTACCCTCCAATTTGTCTCGGCCGAGCGCCC
GGCTGCCTTATGCCTGCAATACAGAATTGGCTGGTGGAAGTCCCTACCGTG
TCACCCACATCCCGCTTCACTTACCACATGGTGTCAGGAATGAGCCTGAAA
CCGCAGGTGAACTACCTGCAAGATTTCTCCTACCAAAGGTCTTTGAAATTTC
GGCCTAAAGGCAAGCCATGTCCCAAAGAGATCTCCAGAGAGTCCAAGGATC
TGGTATGGGAAGAGTGTGTCGCAGACAGCGCTGTTATCCTGCAGAACAATA
CCTTCGGAACCGTGATCGACTGGGCTCCTAGAGGACAGTTTTACCATAATT
GCACCGGTCAAACCCAGTTCTGTCCTAGCGCTCTTGTGTCCCCGACAGTAG
ATAGTGACCTTACCGAAAACTTGGACAAGCACAAACACAAGAAGCTGCAGT
CATTCTACCCGTGGATCTGGGGCGAAAAGGGTATGTCCACTCCCCGCCCGA
AGATGATTTCTCCTGTCTTCGGTCCAGAGCACCCAGAACTGTGGAGACTGA
CTGTGGCCAGTTATAGGCTGAGAATCTGGTCTGGAAACCAGACTATCGAGA
CCCGAGATTACAAACCTTTTTACAGCATCAACCTCAACTCATCCCTTACAGT
CCCACTTCAGTCATGTGTGAAGCCCCCATATATGCTCGTAATTGGCAATATC
GTCATTAAACCCGATTCTCAAACAATAACCTGCGAGAACTGCCGCTTGTTTA
CCTGCATTGACAGTACCTTCGATTGGCAGCATCGAATACTGCTCGTGAGGG
CCCGGGAGGGTGTGTGGATCCCAGTCAGCATGGACAGGCCCTGGGAAGCC
TCTCCATCTATACATATTCTCACAGAGGTGCTCAAGGGAGTCCTGAGCAGAT
CTAAGCGCTTCATCTTCACTCTGATTGCTGTGATCATGGGATTGATCGCAGT
GACAGCCACTGCTAGTGTGGCCGGGGTTGCGCTCCACAGTAGCGTCCAAA
45 
CAGTGTCCTTCGTGGACAATTGGCAGAAGAACTCCACACGGCTGTGGAACT
CTCAGAGTGGAATCGACCAAAAACTGGCGAATCAAATAAACGATCTGAGAC
AGACAGTTATCTGGATGGGTGACCGGCTGATGTCCCTCGAACATAGATTCC
AACTGCAGTGCGACTGGAACACAAGCGACTTCTGCATCACTCCTCAGGTTT
ATAACGAGAGCAAACACCATTGGGATATGGTGCGCCGCCATCTGCAGGGG
CGAGAAGATAACCTGACCCTGGACATTAGCAAGCTGAAGGAACAAATCTTC
GAGGCCTCCCAGAGTCACCTTAATATTGTGCCTGGAGCCGAGGCCCTCGAT
CAGGTAGCAAAAAATCTTTACGAGCTCAATCCAACCACTTGGATTAAGTCTA
TAGGGAACTCTACGGCCATCAATTTTGGAATAATGTGTCTTTGCCTCATCTC
ACTCTTCCTGGTCTGTTGGACATCCAGAAGAATTCTTCGGCAGAACCGCGA
GAACGAGCAGGCATTCATCGCCATGGCACACCTCTATCGCGGTAAAGGCAG
AGAGAACGTGGCTGGGTCCCAGGGCGCCGGCGCCGGCCTGAACGACATC
TTCGAGGCCCAGAAGATCGAGTGGCACGAGTAG 
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